|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent microRNA (miR) studies have revealed that aberrantly elevated miR-34a in obesity directly targets β-Klotho, the obligate coreceptor for both FGF19 and FGF21, and attenuates metabolic signaling of these hormones.
|
27125742 |
2016 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucose kinetics and plasma FGF19 and FGF21 responses to mixed meal ingestion and to glucose-insulin infusion during a hyperinsulinemic-euglycemic clamp procedure, with stable isotope tracer methods, were evaluated in 28 adults with obesity before and after 20% weight loss induced by RYGB (n = 16) or LAGB (n = 12).
|
28938478 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.
|
29266852 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Continuous intracerebroventricular (i.c.v.) administration of FGF21 was found to modulate feeding and energy expenditure in rats with diet-induced obesity, suggesting a central effect by the peptide.
|
28889722 |
2017 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, very recent results from different human cohort studies have shown a paradoxical regulation of plasma FGF21 in obesity and type 2 diabetes as well as other important qualitative differences in the effects and regulation of FGF21 between rodents and humans.
|
19277467 |
2009 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review summarizes what is known about FGF21 in mice and humans with a special focus on this factor's role in glucose and lipid metabolism and in metabolic diseases, such as obesity and type 2 diabetes mellitus.
|
28938407 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association of OSAHS Hypoxia Indicators with Early Renal Injury and Serum Fibroblast Growth Factor 21 in Obese Type 2 Diabetic Patients.
|
31172456 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF-21-transgenic mice were viable and resistant to diet-induced obesity.
|
15902306 |
2005 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals.
|
18252893 |
2008 |
|
Obesity
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We propose that Fgf21 methylation represents a form of epigenetic memory that persists into adulthood, and it may have a role in the developmental programming of obesity.
|
29434210 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, here we describe an approach to increase the endogenous production of FGF21, which if demonstrated functional in humans, could generate a treatment for obesity.
|
28078804 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
A cytokine involved in cellular metabolism, FGF21 is a potential susceptibility gene for obesity and type 2 diabetes.
|
23372041 |
2013 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This is in contrast to the anti-diabetic medication metformin and suggests that the treatment of obesity and diabetes with the combination of FGF21 and AMPK activators merits consideration.
|
28580278 |
2017 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Altogether, our study suggests that n-3-PUFAs influence FGF21 levels in obesity, although the specific mechanisms implicated remain to be elucidated.
|
29766165 |
2018 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent results suggest that FGF21 is highly expressed in hepatocytes under metabolic stress caused by starvation, hepatosteatosis, obesity and diabetes.
|
23590285 |
2013 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A low-calorie, high-carbohydrate/low-fat diet was beneficial for overweight or obese individuals carrying the carbohydrate intake-decreasing allele of the FGF21 variant to improve body composition and abdominal obesity.
|
27581055 |
2016 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF1, FGF10, FGF15/FGF19 and FGF21) have been further recognized as regulators of energy homeostasis, metabolism and adipogenesis, constituting novel therapeutic targets for obesity and obesity-related cardiometabolic disease.
|
27412358 |
2017 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
We tested whether a targeted reduction in hepatic peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), which has been shown to occur with obesity, had a negative impact on the metabolic effects of FGF21.
|
29215172 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that chronic PD retards the development of hypertrigylceridemia and fatty liver in obesity and that this relies on the induction of the hepatokine fibroblast growth factor 21 (FGF21).
|
29751292 |
2018 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collectively, the results of the present study revealed a new mechanism underlying the regulation of hepatic ER stress and FGF21 expression induced by EPO; thus, EPO may be considered as a potential therapeutic agent for the treatment of fatty liver and obesity.
|
31173165 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that betaKlotho (KLB) and endocrine FGF19 and FGF21 redirect FGFR signaling to regulation of metabolic homeostasis and suppression of obesity and diabetes.
|
22442730 |
2012 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity.
|
19702724 |
2009 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 (FGF21) is a potent endocrine regulator with physiological effects on glucose and lipid metabolism and thus garners much attention for its translational potential for the management of obesity and related metabolic syndromes.
|
28559437 |
2017 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of FGF21 and decreased levels of adiponectin in obesity indicate FGF21-adiponectin axis dysfunction.
|
30978696 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin increased serum and muscle FGF21 independent of overweight/obesity or type 2 diabetes, and there were no effects associated with exercise training.
|
28721439 |
2017 |